Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC), AbCellera Biologics (ABCL) and Cytokinetics (CYTK)

Tipranks - Tipranks - Fri Feb 27, 9:09AM CST

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOC – Research Report), AbCellera Biologics (ABCL – Research Report) and Cytokinetics (CYTK – Research Report).

Claim 50% Off TipRanks Premium

Teladoc (TDOC)

Truist Financial analyst Jailendra Singh maintained a Hold rating on Teladoc today. The company’s shares closed last Thursday at $5.31.

According to TipRanks.com, Singh has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -17.3% and a 31.2% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Fortrea Holdings Inc., and Medline, Inc. Class A. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Teladoc with a $7.35 average price target, which is a 54.4% upside from current levels. In a report issued on February 18, BTIG also maintained a Hold rating on the stock.

See today’s best-performing stocks on TipRanks >>

AbCellera Biologics (ABCL)

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on AbCellera Biologics today. The company’s shares closed last Thursday at $3.25.

According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of 17.9% and a 58.7% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Protagonist Therapeutics, and Arvinas Holding Company. ;'>

AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $7.00, representing an 119.4% upside. In a report issued on February 24, TD Cowen also maintained a Buy rating on the stock.

Cytokinetics (CYTK)

In a report released yesterday, Carter Gould from Cantor Fitzgerald maintained a Buy rating on Cytokinetics. The company’s shares closed last Thursday at $61.34.

According to TipRanks.com, Gould is a 4-star analyst with an average return of 6.6% and a 52.9% success rate. Gould covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Gilead Sciences, and Merck & Company. ;'>

Cytokinetics has an analyst consensus of Strong Buy, with a price target consensus of $93.15, implying a 48.8% upside from current levels. In a report issued on February 19, Barclays also maintained a Buy rating on the stock with a $87.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).